Sucralfate

Identification

Name
Sucralfate
Accession Number
DB00364
Description

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers Label, gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances 2,13.

Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form 11,12.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1558.67
Monoisotopic: 1557.6045961
Chemical Formula
C12H35Al9O55S8
Synonyms
  • Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  • Sucralfat
  • Sucralfate
  • Sucralfato
  • Sucralfatum
External IDs
  • CGA-6J
  • OS 202

Pharmacology

Indication

The sucralfate suspension Label and tablet 15 are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence 13,15.

Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2,13.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances 2. In addition, sucralfate acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract 2.

Mechanism of action

The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of sucralfate. There is evidence that sucralfate acts locally to aid in tissue healing, and not systemically Label.

Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen 7,8 preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors 6, leading to an increase in prostaglandins at the gastrointestinal tract lining, which promote the healing of gastrointestinal ulcers 2.

In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% Label. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation 4. Bile salts have been implicated in mucosal injury to the gastrointestinal tract 9,10. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing Label.

TargetActionsOrganism
APepsin A-5
inhibitor
Humans
AFibroblast growth factor 2
agonist
inducer
Humans
APro-epidermal growth factor
inducer
Humans
UFibrinogen
binder
protector
Humans
Absorption

This drug is absorbed from the gastrointestinal tract in very minimal quantities Label. The adsorbed sulfated disaccharide is excreted in the urine 13. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function 13. This number is expected to increase in those with impaired renal function 13.

Volume of distribution

This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions Label.

Protein binding

Sucralfate is bound to plasma proteins, especially albumin and transferrin 13.

Metabolism

This drug is absorbed in very small quantities and is not significantly metabolized Label,13.

Route of elimination

The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours Label,16.

Half-life

The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h 16.

Clearance

Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity 13.

In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids 13.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Overdose

Overdosage has never been observed with sucralfate 13. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies 13. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised 13.

Use in pregnancy

This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health Label.

Use in nursing

Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed Label.

Carcinogenesis

24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedLabel.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirSucralfate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Sucralfate.
AcetaminophenAcetaminophen may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AclidiniumSucralfate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineSucralfate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.
  • Take separate from antacids. Take at least 30 minutes before or after antacids.

Products

Product Images
International/Other Brands
Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CarafateSuspension1 g/10mLOralPhysicians Total Care, Inc.1996-03-12Not applicableUS flag
CarafateTablet1 g/1OralAllergan, Inc.1981-10-30Not applicableUS flag
CarafateSuspension1 g/10mLOralAllergan1993-12-16Not applicableUS flag
CarafateSuspension1 g/10mLOralAtlantic Biologicals Corps1993-12-16Not applicableUS flag
SucralfateSuspension1 g/10mLOralPrecision Dose Inc.2003-08-212021-04-30US flag
SucralfateTablet1 g/1OralRemedy Repack2009-06-182017-02-24US flag
SucralfateSuspension1 g/10mLOralCardinal Health2009-11-19Not applicableUS flag
SucralfateTablet1 g/1OralRemedy Repack2010-05-202010-12-10US flag
SucralfateSuspension1 g/10mLOralPhysicians Total Care, Inc.2005-05-24Not applicableUS flag
SucralfateSuspension1 g/10mLOralVistapharm, Inc.2012-08-16Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-sucralfate - Tab 1gTabletOralApotex Corporation1994-12-31Not applicableCanada flag
Dom-sucralfateTabletOralDominion Pharmacal1999-09-152016-10-25Canada flag
Nu-sucralfate - Tab 1gmTabletOralNu Pharm Inc1994-12-312012-09-04Canada flag
PMS-sucralfateTabletOralPharmascience Inc1999-02-23Not applicableCanada flag
SucralfateTablet1 g/1OralActavis Pharma, Inc.2016-12-052019-07-31US flag
SucralfateTablet1 g/1OralActavis Pharma, Inc.1996-11-012020-03-31US flag0591 078020180913 8702 utnpr1
SucralfateSuspension1 g/10mLOralPar Pharmaceutical Inc.2020-01-27Not applicableUS flag
SucralfateSuspension1 g/10mLOralAmneal Pharmaceuticals LLC2019-12-02Not applicableUS flag65162 06220191206 32104 1jba4b4
SucralfateTablet1 g/1OralLevista, Inc.2009-07-012011-12-31US flag
SucralfateTablet1 g/1Oralbryant ranch prepack1996-11-11Not applicableUS flag00093 2210 98 nlmimage10 b827dc6e
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
A02BX02 — Sucralfate
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
XX73205DH5
CAS number
54182-58-0
InChI Key
IPLJAZDIICJQEL-JTJNLBSYSA-A
InChI
InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;9*+3;;;;;;;;;;;;;;;;;;;;/p-27/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
IUPAC Name
[({[(2R,3R,4S,5R,6R)-6-{[(2S,3S,4R,5R)-3,4-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2,5-bis[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxan-3-yl]oxy}sulfonyl)oxy]alumanediol alumanetriol hydrate
SMILES
O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[[email protected]]1O[[email protected]@](COS(=O)(=O)O[Al](O)O)(O[[email protected]]2O[[email protected]](COS(=O)(=O)O[Al](O)O)[[email protected]@H](OS(=O)(=O)O[Al](O)O)[[email protected]](OS(=O)(=O)O[Al](O)O)[[email protected]]2OS(=O)(=O)O[Al](O)O)[[email protected]@H](OS(=O)(=O)O[Al](O)O)[[email protected]@H]1OS(=O)(=O)O[Al](O)O

References

Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.

US4990610
General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673]
  2. Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9. [PubMed:11019606]
  3. Lam SK: Why do ulcers heal with sucralfate? Scand J Gastroenterol Suppl. 1990;173:6-16. [PubMed:2190306]
  4. Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10. [PubMed:22242022]
  5. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  6. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
  7. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  8. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  9. Gadacz TR, Zuidema GD: Bile acid composition in patients with and without symptoms of postoperative refulx gastritis. Am J Surg. 1978 Jan;135(1):48-52. [PubMed:341732]
  10. Duane WC, Wiegand DM: Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest. 1980 Nov;66(5):1044-9. doi: 10.1172/JCI109932. [PubMed:7430343]
  11. FDA approval, Sucralfate suspension [Link]
  12. Sucralfate tablet FDA approval [Link]
  13. Product monograph, Sulcrate [File]
  14. MedSafe NZ, Sucralfate [File]
  15. Sucralfate FDA label, tablet form [File]
  16. Risk profile of sucralfate [File]
Human Metabolome Database
HMDB0014508
KEGG Compound
C07314
PubChem Compound
70789197
PubChem Substance
46508862
ChemSpider
32701653
RxNav
10156
ChEMBL
CHEMBL2029132
PharmGKB
PA451524
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sucralfate
AHFS Codes
  • 56:28.32 — Protectants
FDA label
Download (217 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentChronic Erosive Gastritis1
4CompletedTreatmentChronic Radiation Proctitis1
4CompletedTreatmentDyspepsia1
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot and Mouth Disease (HFMD) / Herpangina1
0CompletedTreatmentOesophagitis, Eosinophilic1
Not AvailableRecruitingDiagnosticGastroesophageal Reflux / Non-erosive Reflux Esophagitis Disease (NERD)1
Not AvailableWithdrawnDiagnosticDyspepsia / Gastro-esophageal Reflux Disease (GERD) / Non-erosive Reflux Esophagitis Disease (NERD)1

Pharmacoeconomics

Manufacturers
  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
Packagers
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Axcan Pharma Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Giant Food Inc.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Levista Inc.
  • Long Wing International Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merckle GmbH
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nostrum Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Precision Dose Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prime European Therapeuticals SPA
  • Qingdao Pana Life Biochem Co. Ltd.
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sanofi-Aventis Inc.
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Xactdose Inc.
Dosage Forms
FormRouteStrength
Tablet, chewableBuccal500 mg
TabletOral1 g
PowderOral1 G
PowderOral2 G
SuspensionOral20 %
TabletOral500 MG
Tablet, solubleOral1000 mg
Suspension1 g/5ml
Tablet, coatedOral100 mg
Granule, for suspensionOral2 G
Tablet, chewableOral1000 mg
SuspensionOral1 g/10mL
TabletOral1 g/1
PowderNot applicable1 kg/1kg
Powder, for suspensionOral1 G
Powder, for suspensionOral2 G
Granule, for suspensionOral1 G
SuspensionOral1 G/5ML
GelOral1 G/5ML
GelOral2 G/10ML
Tablet1 G
SuspensionOral20 g
SuspensionOral
TabletOral
Prices
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>220https://www.trc-canada.com/product-detail/?S692350
water solubilityInsolublehttps://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx
logP-7.087http://www.molbase.com/en/overview_54182-58-0-moldata-62765.html
pKa 0.43 to 1.19https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx
Predicted Properties
PropertyValueSource
Water Solubility0.774 mg/mLALOGPS
logP0.74ALOGPS
logP-5.9ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count37ChemAxon
Refractivity180.03 m3·mol-1ChemAxon
Polarizability107.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
CarcinogenicityNon-carcinogens0.5356
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent.
Specific Function
Aspartic-type endopeptidase activity
Gene Name
PGA5
Uniprot ID
P0DJD9
Uniprot Name
Pepsin A-5
Molecular Weight
41992.845 Da
References
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840]
  4. Kegg [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
Inducer
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198]
  4. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inducer
General Function
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
Gene Name
EGF
Uniprot ID
P01133
Uniprot Name
Pro-epidermal growth factor
Molecular Weight
133993.12 Da
References
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
4. Fibrinogen
Kind
Group
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
Protector
This group includes the fibrinogen alpha chain, beta chain, and gamma chain.
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  2. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  3. Sucralfate - Drug Summary [Link]

Drug created on June 13, 2005 07:24 / Updated on September 25, 2020 15:13

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates